# Tafolecimab in Hyperlipidemia: A Study of Different Dosing Intervals

> **NCT07712042** · — · NOT_YET_RECRUITING · sponsor: **Mei Gao** · enrollment: 60 (estimated)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** Tafolecimab

## Key facts

- **NCT ID:** NCT07712042
- **Lead sponsor:** Mei Gao
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07712042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07712042, "Tafolecimab in Hyperlipidemia: A Study of Different Dosing Intervals". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07712042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*